Why This Fund Just Made a $55 Million Bet on Dianthus
A prominent fund has poured roughly $55 million into Dianthus as the stock climbs 350%. This article breaks down what...
Incorporating alternative investments into your long-term portfolio can enhance diversification and improve returns.
27,567 articlesA prominent fund has poured roughly $55 million into Dianthus as the stock climbs 350%. This article breaks down what...
Are you debating whether to hold or sell JD.com stock? This jd.com stock analysis: sell? guide breaks down the busine...
DexCom and Insulet sit at the heart of diabetes technology. This in-depth look examines growth drivers, financials, a...
An Axcelis VP Corporate Controller sold 2,574 shares for roughly $422k. This article breaks down what that means, how...
Grandparents are increasingly using a dividend-focused plan to fund college costs, aiming to preserve principal while...
Two biotech contenders, Recursion Pharmaceuticals and Summit Therapeutics, face off in a year of uncertainty and oppo...
Investors are weighing big potential against real-world risk. This article breaks down VK2735, market dynamics, and w...
From repeated loan denials to a growing 10+ unit multifamily portfolio, this deal diary-style story reveals the strat...
Rambus navigates a cooling memory-chip cycle that could weigh on margins even as AI infrastructure demand remains a k...
Shiba Inu showed a notable, double-digit climb this week. This guide breaks down the catalysts—ecosystem upgrades, se...
Investing in rare earths is a long game tied to U.S. policy, global demand, and the pace of production. This guide co...
Biotech earnings chants are rarely about profits for small developers. This guide explains how to read Celcuity's 202...